Table 1.
Characteristics of included studies.
| Author | Publish year | Setting | Clinical trials register No. | Intervention vitamin D3 | Dosage | Female/MaleAge | Statistics of studies |
Refs. | ||
|---|---|---|---|---|---|---|---|---|---|---|
| case | control | p-value | ||||||||
| Martineau | 2011 | UK | NCT00419068 | vitamin D3 2.5 mg |
2, 4 and 6 weeks | NA 30.6 |
36 (95% CI 31.8–40.2) | 43.5 (95% CI 36.5–50.5) |
HR: 1.39; 95% CI 0.90–2.16, P = 0.41 | [10] |
| Daley | 2015 | India | NCT00366470 | vitamin D3 2.5 mg |
0, 2, 4, and 6 weeks | 58/189 42.65 |
43·0 (33·3–52·8) | 42·0 (33·9–50·1) | 0·952 | [12] |
| Mily | 2015 | Bangladesh | NCT01580007 | vitamin D3 500 mg |
Once daily for 2 months | 23/19 27.4 ± 12 |
61.3% (38/62) | 42.2% (27/64) |
0.032 | [14] |
| Salahuddin | 2013 | Saudi Arabia | NCT01130311 | vitamin D3 600,000 IU |
2 doses | 118/141 28.05 ± 61 |
6.68 ± 2.04, 6.3–7.03 | 6.85 ± 2.50, 6.4–7.29 | 0.16 | [15] |
| Tukvadze | 2015 | Georgia | NCT00918086 | vitamin D3 1.25 mg |
Thrice weekly for 8 week | 72/127 33.25 |
29; 95% CI: 24, 36 |
27; 95% CI: 23, 36 | HR: 0.86; 95% CI: 0.63, 1.18; P = 0.33 | [16] |
| Bekele | 2018 | Ethiopia | NCT01698476 | vitamin D3 5000 IU |
FOR 16 weeks | 147/201 30.47 |
1.07 0.43–2.65 P = 0.879 |
1.05 0.42–2.63 P = 0.904 |
NA | [17] |
| Ganmaa | 2017 | Mongolia | NCT01657656 | vitamin D3 3.5 mg |
four oral doses | 134/256 33 |
NA | NA | Adjusted hazard ratio, 1.09; 95% confidence interval, 0.86–1.36; P = 0.48. |
[18] |
| Ralph | 2013 | Indonesia | NCT00677339 | vitamin D3 50,000 IU |
Once daily for 4 weeks | 69/131 27.5 |
59% (44/75) |
65% (52/80) |
Risk difference 7%, 95% CI 29 to 22%. | [19] |